Drug intelligence / Profile preview

EDC ConM SOSIP

Development stage: Unknown
Lead developer: Imperial College London
Modality: Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

EDC ConM SOSIP is a chemically cross-linked HIV-1 envelope glycoprotein trimer immunogen used in experimental HIV vaccine development. It is created by applying a SOSIP (SOluble, Stabilized, cleaved, gp140 trImeric Protein) design to a consensus HIV-1 envelope protein (ConM) and then stabilizing it through chemical cross-linking using 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC). This cross-linking process enhances trimer stability while maintaining protein folding with minimal structural distortion. The immunogen is designed to induce neutralizing antibodies against HIV-1 by presenting a stabilized, native-like envelope structure.

Targets

Env (HIV-1 envelope glycoprotein)

Beyond the preview

Go deeper on EDC ConM SOSIP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDC ConM SOSIP.

Explore the full profile